Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline celebrates its role in supporting the biggest anti-doping operation in the history of the Olympic Games
GSK, Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games celebrating with anti-doping science campaign.
-
US Regulatory Update – Tykerb® (lapatinib)
GSK announced it has withdrawn a sNDA to the FDA for lapatinib with trastuzumab for HER2 (ErbB2)-positive metastatic breast cancer
-
GSK announces positive data from Harmony 8 and completion of clinical registration package for albiglutide in type 2 diabetes
GSK announced data have been received from Phase III Harmony 8 study of cardiovascular safety conducted across the albiglutide programme.
-
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Shionogi-ViiV announced results received from Phase III SINGLE study of dolutegravir in treatment-naive adults with HIV-1.
-
GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states
GSKannounced it has reached an agreement with the US Government, to conclude the Companys ongoing Federal government investigations.
-
GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences
GSK announced it has extended its tender offer to acquire all of the outstanding shares of HGSI for US$13.00 per share 5pm NY 20/07/12
-
GSK continues with tender offer to acquire all outstanding shares of Human Genome Sciences
GSK confirmed receiving an invitation from HGS to participate in its strategic alternatives review process which started in April.
-
GSK receives FDA approval for MenHibrix
GSK plc announced today that the US FDA has approved the vaccine MenHibrix, Haemophilus b Tetanus Toxoid Conjugate Vaccine].
-
Stiefel signs worldwide acquisition and license agreement for Toctino®
Stiefel announced it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea).
-
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes
Phase III study comparing albiglutide to Lispro, were presented today at the ADA Meeting in Philadelphia, USA.
-
GSK extends tender offer for all outstanding shares of Human Genome Sciences
GSK announced it has extended its tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share 5:00pm NY 29/06/12
-
GSK and XenoPort receive FDA approval for Horizant® for postherpetic neuralgia
GSK & XNPT announced today that the FDA has approved Horizant, Extended-Release Tablets for the management of PHN in adults.
-
GSK announces expiration of Hart-Scott-Rodino waiting period for tender offer for HGS
GSK announced that the waiting period under the HSR Act, has expired with respect to GSK tender offer for all the outstanding shares of HGS
-
GSK and EPSRC announce creation of new Chair in Sustainable Chemistry at the University of Nottingham
GSK & EPSRC announced they will contribute to funding for a Chair in Sustainable Chemistry to be based at GSK's Carbon Neutral Laboratory
-
Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade®
GSK's submitted regulatory applications in the EU and US related to eltrombopag to increase platelet counts in patients with chronic hep C
-
GlaxoSmithKline confirms US District Court ruling in Pronova BioPharma’s favour on Lovaza™ patents
GSK which has the marketing rights for Lovaza in the US and Puerto Rico, confirmed that U.S. District Judge Sue Lewis Robinson...
-
GSK secures future of local playing fields with Fields in Trust as part of London 2012 legacy
GSK entered a partnership with FIT to secure the future of its Swyncombe Avenue Playing Fields, where hundreds of local people enjoy sport
-
GSK announces start of Phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma
The start of a Phase III programme evaluating the combination of dabrafenib, its BRAF inhibitor, and trametinib, its MEK inhibitor,
-
GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with certain advanced soft tissue sarcomas
GSK announced that the EMA CHMP has issued a positive opinion recommending marketing authorisation for Votrient for the treatment of STS.
-
Innovative public-private collaboration launches to tackle antibiotic research
GSK & AZN launch a pioneering approach to antibiotic research in Europe and address key barriers to the development of antibiotics.